Form 4: Fennec Pharmaceuticals Executive Awarded 10,000 Restricted Share Units

Terry Evans, Chief Commercial Officer of Fennec Pharmaceuticals, received 10,000 restricted share units under the company's 2020 Equity Incentive Plan.

Summary

• Terry Evans, the Chief Commercial Officer of Fennec Pharmaceuticals, was granted 10,000 restricted share units on March 28, 2025.
• These units were awarded under the company's 2020 Equity Incentive Plan.
• The shares will vest over time, starting with one-third vesting on March 28, 2026.
• Following the Vesting Commencement Date, one twenty-fourth of the shares will be released from restriction as of the last day of each month.
• By February 29, 2028, all shares will be fully vested.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. It's a neutral-positive event.

Positives

• The awarding of restricted share units aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Future Outlook

The vesting schedule suggests a continued commitment from the executive to the company's long-term success.

Industry Context

Granting restricted share units is a common practice in the pharmaceutical industry to incentivize executives and align their interests with shareholders.

Comparison to Industry Standards

• Many pharmaceutical companies use equity-based compensation, such as restricted stock units (RSUs) or stock options, to incentivize their executives.
• The vesting schedules for these awards typically range from three to five years, which is consistent with the vesting schedule outlined in this document.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize similar equity compensation plans for their executive teams.

Stakeholder Impact

• Shareholders may view this as a positive sign, indicating that the company is investing in its leadership.
• Employees may see this as a sign of stability and opportunity within the company.

Key Dates

Keywords

Restricted Share Units, Fennec Pharmaceuticals, Equity Incentive Plan, Vesting, Executive Compensation, Form 4